Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease

Hepatology

Volumn 54, Issue 1, 2011, Pages 377-378

  Shen, Liang ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; INSULIN SENSITIZING AGENT; PROBIOTIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; LETTER; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; FATTY LIVER; HUMANS; HYPOLIPIDEMIC AGENTS; PROBIOTICS; RISK FACTORS;

EID: 79959548064     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24213     Document Type: Letter

References (5)

1. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51: 1947-1953.
2. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. HEPATOLOGY 2010; 52: 1156-1161.
3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
4. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010; 3: 121-137.
5. Satapathy SK, Sanyal AJ. Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 2010; 21: 668-675.